Casi pharmaceuticals receives fda clearance on the investigational new drug (ind) application for cid-103 in immune thrombocytopenia (itp)

Beijing , may 15, 2024 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced today the following: on april 12, 2024 casi submitted the ind application to the fda for cid-103 to support a phase 1/2 study of cid-103 in adults with chronic immune thrombocytopenia (itp). on may 13, 2024 casi received a letter from fda indicating that study may proceed.
CASI Ratings Summary
CASI Quant Ranking